{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:21:50Z","timestamp":1794680510472,"version":"4.9.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","award":["R302-A17351"],"award-info":[{"award-number":["R302-A17351"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.lanepe.2026.101879","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:57:59Z","timestamp":1790315879000},"page":"101879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2640-5225","authenticated-orcid":false,"given":"Signe Lenora","family":"Risumlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line Bjerregaard","family":"Stick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2792-9218","authenticated-orcid":false,"given":"Ane","family":"Appelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Richter","family":"Vogelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Nyhuus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai Aagaard","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luit","family":"Penninga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-5999","authenticated-orcid":false,"given":"Mette","family":"van Overeem Felter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Josipovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-1043","authenticated-orcid":false,"given":"Peter N\u00f8rgaard","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101879_bib1","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s00464-014-3545-3","article-title":"Decision-making in colorectal cancer tumour board meetings: results of a prospective observational assessment","volume":"28","author":"Shah","year":"2014","journal-title":"Surg Endosc"},{"key":"10.1016\/j.lanepe.2026.101879_bib2","article-title":"Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): a nationwide prospective intervention study","volume":"3","author":"Osterlund","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101879_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10585-015-9719-0","article-title":"Nationwide trends in incidence, treatment, and survival of colorectal cancer patients with synchronous metastases","volume":"32","author":"van der Geest","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.lanepe.2026.101879_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.canep.2014.04.004","article-title":"Patterns of metachronous metastases after curative treatment of colorectal cancer","volume":"38","author":"van Gestel","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.lanepe.2026.101879_bib5","article-title":"Synchronous and metachronous liver metastases in patients with colorectal cancer","volume":"65","author":"Okholm","year":"2018","journal-title":"Dan Med J"},{"key":"10.1016\/j.lanepe.2026.101879_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100470","article-title":"Predictive preoperative clinical score for patients with liver-only oligometastatic colorectal cancer","volume":"7","author":"Filippini Vel\u00e1zquez","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.lanepe.2026.101879_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Cremolini","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, version 2.2021, NCCN Clinical Practice Guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.lanepe.2026.101879_bib11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): long-term results of a randomized phase III trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.surg.2018.01.004","article-title":"Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?","volume":"163","author":"Creasy","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.lanepe.2026.101879_bib13","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/1471-2407-14-810","article-title":"Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma","volume":"14","author":"Hackl","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lanepe.2026.101879_bib14","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.21037\/jgo-22-1183","article-title":"Stereotactic body radiation therapy for colorectal cancer liver metastases","volume":"15","author":"Lukovic","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s12029-022-00900-5","article-title":"Oligometastatic colorectal cancer: a review of definitions and patient selection for local therapies","volume":"54","author":"Miller","year":"2023","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.lanepe.2026.101879_bib16","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib17","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.3390\/jcm14228016","article-title":"The emerging role of ablation in the treatment of primary and metastatic cancer of the liver","volume":"14","author":"Komorowski","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.lanepe.2026.101879_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(24)00660-0","article-title":"Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial","volume":"26","author":"van der Lei","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11912-022-01248-6","article-title":"Microwave ablation, radiofrequency ablation, irreversible electroporation, and stereotactic ablative body radiotherapy for intermediate-size (3\u20135 cm) unresectable colorectal liver metastases: a systematic review and meta-analysis","volume":"24","author":"Nieuwenhuizen","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.lanepe.2026.101879_bib20","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.3390\/cancers15174346","article-title":"Efficacy of thermal ablation for small-size (0\u20133 cm) versus intermediate-size (3\u20135 cm) colorectal liver metastases: results from the Amsterdam colorectal liver metastases registry (AmCORE)","volume":"15","author":"Dijkstra","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lanepe.2026.101879_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/107327481602300105","article-title":"Stereotactic body radiotherapy in the management of oligometastatic disease","volume":"23","author":"Ahmed","year":"2016","journal-title":"Cancer Control"},{"key":"10.1016\/j.lanepe.2026.101879_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00432-014-1833-x","article-title":"Final results of a phase II trial of stereotactic body radiotherapy for patients with inoperable liver metastases from colorectal cancer","volume":"141","author":"Scorsetti","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib23","article-title":"Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumours of colorectal cancer","volume":"20","author":"Kang","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2026.101879_bib24","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.3390\/cancers13174303","article-title":"Thermal ablation versus stereotactic ablative body radiotherapy to treat unresectable colorectal liver metastases: a comparative analysis from the prospective Amsterdam CORE registry","volume":"13","author":"Nieuwenhuizen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lanepe.2026.101879_bib25","first-page":"98","article-title":"Technical design and concept of a 0.35 T MR-Linac","volume":"18","author":"Kl\u00fcter","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109448","article-title":"Interfractional dose accumulation for MR-guided liver SBRT: variation among algorithms is highly patient- and fraction-dependent","volume":"182","author":"Wahlstedt","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lanepe.2026.101879_bib28","series-title":"Common terminology criteria for adverse events (CTCAE)","year":"2017"},{"key":"10.1016\/j.lanepe.2026.101879_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","article-title":"The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases","volume":"18","author":"Andratschke","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lanepe.2026.101879_bib30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10555-025-10300-3","article-title":"Towards a personalized utilization of stereotactic body radiotherapy for the management of liver metastases in solid tumors","volume":"44","author":"Laurent","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.lanepe.2026.101879_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx031","article-title":"Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumour genotype","volume":"109","author":"Hong","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lanepe.2026.101879_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.radonc.2020.02.008","article-title":"Association of tumour genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer","volume":"146","author":"Jethwa","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib33","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(24)01595-2","article-title":"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial","volume":"404","author":"Adam","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101879_bib34","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1016\/S1470-2045(26)00114-2","article-title":"International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards","volume":"27","author":"Laimer","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanepe.2026.101879_bib35","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00270-023-03498-8","article-title":"Unresectable intermediate-size (3\u20135 cm) colorectal liver metastases: stereotactic ablative body radiotherapy versus microwave ablation (COLLISION-XL): protocol of a phase II\/III multicentre randomised controlled trial","volume":"46","author":"van der Lei","year":"2023","journal-title":"Cardiovasc Interv Radiol"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T17:43:03Z","timestamp":1794678183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":35,"alternative-id":["S2666776226002917"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101879","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101879","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101879"}}